Chromosome Abnormality
15
2
2
7
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
13.3%
2 terminated out of 15 trials
77.8%
-8.7% vs benchmark
7%
1 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (15)
Embryo Selection by Noninvasive Preimplantation Genetic Test
RCT Study to Validate niPGT-A Clinical Benefit.
Structural Chromosome Rearrangements and Brain Disorders
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
Biocollection in MyeloDysplastic Syndrome (P-MDS)
Multi-center Study to Validate niPGT-A
Time Lapse Assisted Embryo Selection Versus Non Invasive PGT-A Assisted Embryo Selection
Invasive PGT-A Embryo Selection Versus Non Invasive PGT-A Assisted Embryo Selection
Post-operative Lite Run Study
Clinical Value of Mosaicism Diagnosis on the Trophectoderm Biopsies
Validation of a NICS Method Using the Culture Medium
Efficacy of Counseling for Prenatal Screening and Diagnostic Tests on Pregnant Women: Randomised Controlled Study
Prenatal Screening, Diagnosis and Intrauterine Intervention of Fetal Abnormal Chromosome and Structure in Twins Pregnancy
Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib